Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

18
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
18
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

847
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
847
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

24
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
24
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
Mitral Regurgitation II: Clinical Features and Diagnostic Tests01:23

Mitral Regurgitation II: Clinical Features and Diagnostic Tests

22
Mitral regurgitation (MR) is a valvular heart disorder in which the mitral valve fails to close tightly, allowing blood to leak backward into the heart. Understanding the clinical manifestations, assessment, diagnostic findings, and medical management of MR is crucial to effectively managing affected patients.Clinical Manifestations of Mitral RegurgitationMitral regurgitation can be acute or chronic, each presenting differently and requiring different approaches:1. Acute Mitral...
22

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction for: miR-21 upregulation exacerbates pressure overload-induced cardiac hypertrophy in aged hearts.

Aging·2026
Same author

Cardiac extracellular vesicle proteomics identifies mitochondrial and contractile dysfunction in carbon monoxide poisoning and their reversal by hyperbaric oxygen therapy.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Corrigendum to "Development and evaluation of clotrimazole microemulsions for topical application: Effects of HLB value of surfactant mixture and cosurfactant type on formulation design" [International Journal of Pharmaceutics: X Volume 11, (June 2026), 100469].

International journal of pharmaceutics: X·2026
Same author

Clinical outcomes of tricuspid transcatheter edge-to-edge repair in patients with tricuspid regurgitation.

Frontiers in medicine·2026
Same author

DNMT1-mediated central amygdala to locus coeruleus circuit contributes to chronic pain-related depression in mice.

Acta pharmacologica Sinica·2026
Same author

2026 Expert Consensus Recommendations on Hypertrophic Cardiomyopathy: A Report of the Task Force of the Taiwan Society of Cardiology.

Acta Cardiologica Sinica·2026

Related Experiment Video

Updated: Jul 11, 2025

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

1.7K

Ivabradine could not decrease mitral regurgitation triggered atrial fibrosis and fibrillation compared with

Wei-Chieh Lee1,2,3, Yu-Wen Lin2, Jhih-Yuan Shih1,2

  • 1School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.

ESC Heart Failure
|November 14, 2023
PubMed
Summary

Carvedilol demonstrated superior efficacy over ivabradine in mitigating mitral regurgitation (MR)-induced cardiac damage in rats. Carvedilol reduced cardiac fibrosis, apoptosis, and atrial fibrillation (AF) inducibility more effectively than ivabradine.

Keywords:
ApoptosisAtrial fibrillationCarvedilolIvabradineMitral regurgitation

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

681

Related Experiment Videos

Last Updated: Jul 11, 2025

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

1.7K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

681

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Ivabradine is a heart failure (HF) treatment reducing heart rate (HR).
  • Degenerative mitral regurgitation (MR) is linked to HF and atrial fibrillation (AF).
  • Limited studies compare ivabradine and beta-blockers in MR.

Purpose of the Study:

  • To compare the therapeutic effects of ivabradine and carvedilol on MR.
  • To investigate their impact on cardiac function and arrhythmogenesis in a rat model.

Main Methods:

  • MR was surgically induced in Sprague-Dawley rats.
  • Rats received ivabradine or carvedilol for 4 weeks.
  • Echocardiography, hemodynamic studies, and postmortem tissue analysis were performed.

Main Results:

  • Neither drug significantly improved MR-induced myocardial dysfunction.
  • Carvedilol mitigated MR-induced chamber dilatation and decreased compliance.
  • Carvedilol reduced AF duration and inducibility, cardiac fibrosis, and apoptosis more than ivabradine.

Conclusions:

  • Carvedilol showed better effects than ivabradine on reversing MR-induced cardiac fibrosis, apoptosis, and arrhythmogenesis.
  • Carvedilol more effectively suppressed AF and HCN4 compared to ivabradine.
  • Further research is needed to confirm these findings.